KLRB1 and glioma: CD161, which is encoded by killer cell lectin-like receptor subfamily B member 1 (KLRB1), has recently been proposed as a potential inhibitory receptor and a promising novel target for immunotherapeutic treatments of glioma (Mathewson et al., 2021).